Evaluation of clinical phenotype, survival, and circulating tumor cell (CTC) enumeration in men with metastatic castration-resistant prostate cancer (mCRPC).

被引：0
|
作者：
Bitting, Rhonda Lynn
Healy, Patrick
Halabi, Susan
George, Daniel J.
Ko, Jung Hyun
Armstrong, Andrew J.
机构：
[1] Duke Canc Inst, Durham, NC USA
[2] Duke Univ Med Ctr, Durham, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5031
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Avelumab in metastatic castration-resistant prostate cancer (mCRPC).
    Fakhrejahani, Farhad
    Madan, Ravi Amrit
    Dahut, William L.
    Karzai, Fatima
    Cordes, Lisa M.
    Schlom, Jeffrey
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [22] Circulating tumor cells in metastatic castration-resistant prostate cancer
    Brian I. Rini
    Current Oncology Reports, 2009, 11 : 163 - 164
  • [23] Circulating tumor DNA (ctDNA) and correlations with clinical prognostic factors in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Khalaf, Daniel
    Annala, Matti
    Beja, Kevin
    Vandekerkhove, Gillian
    Zulfiqar, Muhammad
    Finch, Daygen L.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [24] Molecular and genomic characterization of invasive circulating tumor cells (iCTCs) from men with metastatic castration-resistant prostate cancer (mCRPC)
    Friedlander, Terence W.
    Premasekharan, Gayatri
    Vy Ngo
    Doty, Shaun
    Harris, Anna
    Winter, Michael
    Gilbert, Elizabeth
    Craik, Charles
    Paris, Pamela
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [25] Molecular and genomic characterization of invasive circulating tumor cells (iCTCs) from men with metastatic castration-resistant prostate cancer (mCRPC).
    Friedlander, Terence W.
    Premasekharan, Gayatri
    Ngo, Vy
    Hang, Evelyn
    Graff, Julie Nicole
    Ryan, Charles J.
    Paris, Pamela
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [26] Predictive biomarkers in circulating tumor cells to direct management metastatic castration-resistant prostate cancer (mCRPC)
    Scher, Howard I.
    Schonhoft, Joseph
    Dittamore, Ryan
    CANCER RESEARCH, 2019, 79 (13)
  • [27] Molecular characterization of circulating tumor cells (CTC) and CTC. subpopulations in baseline and progressive metastatic castration resistant prostate cancer (mCRPC)
    Dittamore, Ryan
    Louw, Jessica
    Krupa, Rachel
    Danila, Daniel Costin
    Arslan, Zaina
    Schreiber, Nicole A.
    Bales, Natalee
    Marrinucci, Dena
    Scher, Howard I.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [28] Chromosomal instability (CIN) biomarker in circulating tumor cells (CTC) may predict for therapy resistance in metastatic castration-resistant prostate cancer (mCRPC)
    Keegan, N. M.
    Schonhoft, J.
    Barnett, E.
    Cohn, E. D.
    Zhao, J. L.
    Carbone, E. A.
    Zanone, M. R.
    Anderson, A.
    Wenstrup, R.
    Scher, H. I.
    ANNALS OF ONCOLOGY, 2021, 32 : S653 - S653
  • [29] Analysis of genomic alterations in matched circulating tumor cell DNA (CTC DNA) and plasma tumor DNA (ctDNA) in men with metastatic castration resistant prostate cancer (mCRPC).
    Gupta, Santosh
    Hovelson, Daniel H.
    Tomlins, Scott A.
    Kemeny, Gabor
    Liu, Chia-Jen
    George, Daniel J.
    Rothwell, Colin
    Anand, Monika
    Nanus, David M.
    Giannakakou, Paraskevi
    Gregory, Simon
    Armstrong, Andrew J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [30] Clinical significance of CTC enumeration on the Epic Sciences platform in metastatic castration-resistant prostate cancer (mCRPC) patients treated with AR signaling inhibitors (ARSi).
    Schonhoft, Joseph
    Gill, Audrey
    Graf, Ryon P.
    Jendrisak, Adam
    Barnett, Ethan
    Benoliel, Hannah
    Carbone, Emily
    Tubbs, Alisa
    Orr, Sarah
    Byun, Jiyun
    Wenstrup, Rick
    Scher, Howard, I
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345